Hikal Q1 FY27 results (Apr–Jun 2026) and concall

Healthcare · Concall AI · Call held 6 Aug 2026

Company page: Hikal share price, financials & guidance record

Hikal Limited reported a revenue of ₹403 crores and an EBITDA margin of 9.2% for Q1 FY27, with PAT at ₹(-7) crores. The company is in a recovery phase, strengthening its Pharma, Crop Protection, and Animal Health businesses, and launching a new Personal Care division. Despite challenges like FDA remediation costs and pricing pressure in Crop Protection, Hikal is optimistic about accelerated growth in H2 FY27 and beyond, driven by regulatory milestones and CDMO contributions.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 5.9%, net profit up 67.0% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	453	448	552	380	319 −30%	494 +10%	519 −6%	403 +6%
Expenses	378	376	429	355	311	412	414	366
EBITDA	75	72	123	25	7 −90%	83 +15%	105 −15%	37 +47%
Margin	17%	16%	22%	7%	2%	17%	20%	9%
Other income	0	4	1	1	2	-35	-40	11
Interest	19	19	18	17	15	16	15	15
Depreciation	32	33	38	39	41	41	42	43
Profit before tax	25	24	68	-30	-47 −290%	-9 −139%	8 −88%	-10 +67%
Tax rate	26%	28%	27%	-26%	-26%	-36%	-73%	-25%
Net profit	18	17	50	-22	-35 −291%	-6 −134%	14 −71%	-7 +67%
EPS	1.48	1.39	4.07	-1.82	-2.83	-0.48	1.17	-0.60

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Healthcare earnings calls